Leerink Partnrs Issues Negative Estimate for BCYC Earnings

Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - Investment analysts at Leerink Partnrs decreased their Q1 2025 EPS estimates for Bicycle Therapeutics in a report issued on Tuesday, February 25th. Leerink Partnrs analyst J. Chang now anticipates that the company will post earnings of ($0.85) per share for the quarter, down from their previous forecast of ($0.84). The consensus estimate for Bicycle Therapeutics' current full-year earnings is ($3.06) per share. Leerink Partnrs also issued estimates for Bicycle Therapeutics' Q3 2025 earnings at ($0.87) EPS, Q4 2025 earnings at ($0.89) EPS and FY2025 earnings at ($3.46) EPS.

Bicycle Therapeutics (NASDAQ:BCYC - Get Free Report) last announced its quarterly earnings results on Tuesday, February 25th. The company reported ($0.75) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.85) by $0.10. Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The company had revenue of $3.70 million for the quarter, compared to analysts' expectations of $5.47 million. During the same quarter in the previous year, the company earned ($1.16) earnings per share. Bicycle Therapeutics's quarterly revenue was down 30.2% on a year-over-year basis.

BCYC has been the subject of a number of other reports. Stephens reissued an "equal weight" rating and set a $15.00 price target on shares of Bicycle Therapeutics in a research report on Wednesday, January 22nd. Needham & Company LLC reiterated a "buy" rating and set a $30.00 target price on shares of Bicycle Therapeutics in a report on Wednesday, February 26th. B. Riley dropped their price target on Bicycle Therapeutics from $28.00 to $17.00 and set a "neutral" rating on the stock in a research report on Friday, December 13th. HC Wainwright reaffirmed a "buy" rating and set a $33.00 price objective on shares of Bicycle Therapeutics in a research report on Wednesday, February 26th. Finally, JMP Securities lowered their price objective on Bicycle Therapeutics from $32.00 to $26.00 and set a "market outperform" rating for the company in a research note on Wednesday, December 18th. Two analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. According to MarketBeat, Bicycle Therapeutics has an average rating of "Moderate Buy" and a consensus target price of $29.14.

Bicycle Therapeutics Trading Down 3.2 %

Shares of BCYC stock traded down $0.33 during midday trading on Friday, reaching $10.14. 462,366 shares of the stock were exchanged, compared to its average volume of 302,289. Bicycle Therapeutics has a 1 year low of $10.07 and a 1 year high of $28.67. The firm has a market cap of $700.13 million, a PE ratio of -3.08 and a beta of 0.93. The company's 50 day moving average is $13.11 and its two-hundred day moving average is $19.19.

Insider Activity at Bicycle Therapeutics

In related news, Director Bros. Advisors Lp Baker acquired 985,397 shares of the firm's stock in a transaction dated Friday, December 13th. The stock was purchased at an average cost of $13.76 per share, with a total value of $13,559,062.72. Following the completion of the acquisition, the director now directly owns 9,537,643 shares of the company's stock, valued at approximately $131,237,967.68. This trade represents a 11.52 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Santiago Arroyo sold 4,943 shares of the firm's stock in a transaction that occurred on Thursday, January 2nd. The stock was sold at an average price of $14.09, for a total transaction of $69,646.87. Following the completion of the sale, the insider now owns 69,057 shares in the company, valued at $973,013.13. This represents a 6.68 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 27,677 shares of company stock valued at $392,413. 8.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Bicycle Therapeutics

A number of institutional investors and hedge funds have recently modified their holdings of the company. Assetmark Inc. bought a new position in Bicycle Therapeutics in the third quarter valued at about $34,000. Barclays PLC increased its holdings in Bicycle Therapeutics by 878.3% during the fourth quarter. Barclays PLC now owns 2,612 shares of the company's stock valued at $37,000 after buying an additional 2,345 shares during the last quarter. Avior Wealth Management LLC purchased a new stake in Bicycle Therapeutics during the fourth quarter valued at approximately $57,000. China Universal Asset Management Co. Ltd. raised its stake in shares of Bicycle Therapeutics by 30.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 9,329 shares of the company's stock worth $131,000 after buying an additional 2,191 shares during the period. Finally, JPMorgan Chase & Co. raised its stake in Bicycle Therapeutics by 26.8% during the 3rd quarter. JPMorgan Chase & Co. now owns 8,424 shares of the company's stock worth $191,000 after acquiring an additional 1,782 shares during the period. 86.15% of the stock is currently owned by hedge funds and other institutional investors.

Bicycle Therapeutics Company Profile

Bicycle Therapeutics plc, a clinical-stage biopharmaceutical company, develops a class of medicines for diseases that are underserved by existing therapeutics in the United States and the United Kingdom. Its product pipeline comprising BT8009, a bicycle toxin conjugate (BTC) which is in phase I/II/III clinical trial for the treatment of high nectin-4 expressing tumors; BT5528, a BTC which is in phase I/II clinical trial for the treatment of Ephrin type A receptor 2 expressing tumor; BT7480, a Bicycle TICA molecule which is in phase I/II targeting Nectin-4 and agonizing CD137; and BT7455, a Bicycle TICA molecule targeting Ephrin type A receptor 2 and CD137 and is in preclinical trial.